DOW JONES28,992.41-227.57 -0.78%
S&P 5003,337.75-35.48 -1.05%
NASDAQ9,576.59-174.38 -1.79%

Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $121

Morgan Stanley maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $120 to $121.

Benzinga · 01/17/2020 13:28

Morgan Stanley maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $120 to $121.